SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences:
- H.C. Wainwright 25th Annual Global Investment Conference
Format: Presentation
Date: Tuesday September 12, 2023
Location: New York, NY
Please click here to access the pre-recorded presentation (available September 11 at 7:00 a.m. ET)
- Morgan Stanley 21st Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 13, 2023
Time: 2:55 p.m. ET
Location: New York, NY
Please click here to access the live webcast
Archived replays can be accessed through the Events & Presentations section of the Senti Bio website and will be available for approximately 90 days following each event.
About Senti Bio
Senti Biosciences is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. Senti Bio's wholly-owned pipeline utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships with Spark Therapeutics and BlueRock Therapeutics.
Forward-Looking Statements
This press release and document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act ...